BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang X, Lv X, Tang S, Mei L, Li Y, Zhang J, Jiang J, Peng Z, Song D. Discovery and evolution of aloperine derivatives as a new family of HCV inhibitors with novel mechanism. European Journal of Medicinal Chemistry 2018;143:1053-65. [DOI: 10.1016/j.ejmech.2017.12.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Zhou HF, Wang FX, Sun F, Liu X, Rong SJ, Luo JH, Yue TT, Xiao J, Yang CL, Lu WY, Luo X, Zhou Q, Zhu H, Yang P, Xiong F, Yu QL, Zhang S, Wang CY. Aloperine Ameliorates IMQ-Induced Psoriasis by Attenuating Th17 Differentiation and Facilitating Their Conversion to Treg. Front Pharmacol 2022;13:778755. [PMID: 35721119 DOI: 10.3389/fphar.2022.778755] [Reference Citation Analysis]
2 Zhou H, Li J, Sun F, Wang F, Li M, Dong Y, Fan H, Hu D. A Review on Recent Advances in Aloperine Research: Pharmacological Activities and Underlying Biological Mechanisms. Front Pharmacol 2020;11:538137. [PMID: 33536900 DOI: 10.3389/fphar.2020.538137] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Li W, Li Y, Zhao Y, Ren L. The protective effects of aloperine against ox-LDL-induced endothelial dysfunction and inflammation in HUVECs. Artif Cells Nanomed Biotechnol 2020;48:107-15. [PMID: 31852304 DOI: 10.1080/21691401.2019.1699816] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
4 Song G, Huang Y, Xiong M, Yang Z, Liu Q, Shen J, Zhao P, Yang X. Aloperine Relieves Type 2 Diabetes Mellitus via Enhancing GLUT4 Expression and Translocation. Front Pharmacol 2020;11:561956. [PMID: 33568989 DOI: 10.3389/fphar.2020.561956] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Lee JC, Lin CK, Tseng CK, Chen YL, Tzeng CC, Tseng CH. Discovery of 3-Amino-2-Hydroxypropoxyisoflavone Derivatives as Potential Anti-HCV Agents. Molecules 2018;23:E2863. [PMID: 30400244 DOI: 10.3390/molecules23112863] [Reference Citation Analysis]
6 Wang K, Guo Z, Bao Y, Pang Y, Li Y, He H, Song D. Structure-Activity Relationship of Aloperine Derivatives as New Anti-Liver Fibrogenic Agents. Molecules 2020;25:E4977. [PMID: 33121156 DOI: 10.3390/molecules25214977] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Wang K, Wu JJ, Xin-Zhang, Zeng QX, Zhang N, Huang WJ, Tang S, Wang YX, Kong WJ, Wang YC, Li YH, Song DQ. Discovery and evolution of 12N-substituted aloperine derivatives as anti-SARS-CoV-2 agents through targeting late entry stage. Bioorg Chem 2021;115:105196. [PMID: 34333425 DOI: 10.1016/j.bioorg.2021.105196] [Reference Citation Analysis]
8 Zeng QX, Wang K, Zhang X, Shi YL, Dou YY, Guo ZH, Zhang XT, Zhang N, Deng HB, Li YH, Song DQ. Structure-activity relationship and biological evaluation of 12 N-substituted aloperine derivatives as PD-L1 down-regulatory agents through proteasome pathway. Bioorg Chem 2021;117:105432. [PMID: 34678602 DOI: 10.1016/j.bioorg.2021.105432] [Reference Citation Analysis]
9 Ti H, Zhuang Z, Yu Q, Wang S. Progress of Plant Medicine Derived Extracts and Alkaloids on Modulating Viral Infections and Inflammation. Drug Des Devel Ther 2021;15:1385-408. [PMID: 33833499 DOI: 10.2147/DDDT.S299120] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Liu F, Liu T, Li H. Aloperine inhibits the progression of non-small-cell lung cancer through the PI3K/Akt signaling pathway. Cancer Cell Int 2021;21:662. [PMID: 34895234 DOI: 10.1186/s12935-021-02361-5] [Reference Citation Analysis]
11 Tang S, Wang C, Li YH, Niu TY, Zhang YH, Pang YD, Wang YX, Kong WJ, Song DQ. Structure-activity relationship and hypoglycemic activity of tricyclic matrines with advantage of treating diabetic nephropathy. Eur J Med Chem 2020;201:112315. [PMID: 32603982 DOI: 10.1016/j.ejmech.2020.112315] [Reference Citation Analysis]
12 Yu HI, Shen HC, Chen SH, Lim YP, Chuang HH, Tai TS, Kung FP, Lu CH, Hou CY, Lee YR. Autophagy Modulation in Human Thyroid Cancer Cells following Aloperine Treatment. Int J Mol Sci 2019;20:E5315. [PMID: 31731481 DOI: 10.3390/ijms20215315] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
13 Tahir M, Ali S, Zhang W, Lv B, Qiu W, Wang J. Aloperine: A Potent Modulator of Crucial Biological Mechanisms in Multiple Diseases. Biomedicines 2022;10:905. [DOI: 10.3390/biomedicines10040905] [Reference Citation Analysis]
14 Lv XQ, Zou LL, Tan JL, Li H, Li JR, Liu NN, Dong B, Song DQ, Peng ZG. Aloperine inhibits hepatitis C virus entry into cells by disturbing internalisation from endocytosis to the membrane fusion process. Eur J Pharmacol 2020;883:173323. [PMID: 32622669 DOI: 10.1016/j.ejphar.2020.173323] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Qiu M, Liu J, Feng P, Su Y, Guo R, Shi F, Wang S, Zhao B. Cytochrome P450s regulates aloperine-induced pathological changes in mouse liver and kidney. Res Vet Sci 2020;132:97-100. [PMID: 32544634 DOI: 10.1016/j.rvsc.2020.06.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]